An interventional, randomized, double-blind, placebo-controlled study will be conducted to investigate the effect of a probiotic strain on the immune response in participants positive for SARS-CoV-2 infection.

The study duration will be 28 days, which includes 4 weeks product administration. Participants will be randomized assigned to one of the two study groups: the control group with placebo consumption and a probiotic consumption group.

Inclusion Criteria:

• Adult (18-65 years).
• Mild infection by SARS-CoV-2 detected by PCR or Antigen.
• Onset of COVID-19 symptoms up to 5 days before the day of inclusion
• Without hospitalization or oxygen supplementation on the day of inclusion.
• Signed written informed consent

Exclusion Criteria:

• Serious SARS-CoV-2 infection requiring hospitalization or oxygen supply
• Chronic diseases under regular medication (eg asthma, allergic rhinitis ...)
• Congenital or acquired immunodeficiency
• Body Mass Index (BMI)> 30
• Coagulation disorders
• Short bowel syndrome or any surgery on the gastrointestinal tract.
• Metabolic disorders (diabetes, etc.).
• Heart failure and cardiac medical history
• Pregnant women.
• HIV positive.
• Immunocompromised
• History of significant gastrointestinal diseases
• Use of other probiotics during the last month.
• Uncertainty about the willingness or ability of the participant to comply with the requirements of the protocol.